# Mounjaro vs Ozempic: what actually differs

> Mounjaro vs Ozempic compared: how each works, what the SURPASS-2 and SURMOUNT-5 head-to-head trials found, side effects, and what to ask your prescriber.

Canonical page: https://handlehealth.co/mounjaro-vs-ozempic · Category: Comparisons · Last checked against sources: 2026-09-23

If you're weighing Mounjaro vs Ozempic, you want facts rather than hype. This comparison draws on the prescribing labels and the two head-to-head trials of their medicines, tirzepatide and semaglutide: how each works, how they compared on blood sugar and weight, which side effects to expect, and what to ask your prescriber. It never recommends one over the other.

## In short

- Mounjaro is tirzepatide from Eli Lilly, which activates two gut-hormone receptors (GIP and GLP-1); Ozempic is semaglutide from Novo Nordisk, which activates the GLP-1 receptor only.[1][2]
- Both are once-weekly injections approved in the US for type 2 diabetes; in the UK, Mounjaro is also licensed for weight management.[1][2][9]
- In SURPASS-2, a 40-week head-to-head trial in 1,879 adults with type 2 diabetes on metformin, HbA1c fell by an average of 2.0 to 2.3 points on Mounjaro (5 to 15 mg) and 1.9 points on semaglutide 1 mg, and weight by 7.6 to 11.2 kg against 5.7 kg.[1][3]
- In SURMOUNT-5, a 72-week trial in 751 adults with obesity, or overweight with a weight-related condition, and without type 2 diabetes, average weight change was −20.2% on tirzepatide (10 or 15 mg) and −13.7% on semaglutide (1.7 or 2.4 mg, the strengths sold as Wegovy), counting everyone randomized.[4][8]
- Stomach side effects are the most common with both, mostly while the dose is being stepped up, and which medicine fits you is a decision for you and your prescriber.[1][2]

## Mounjaro vs Ozempic at a glance

|  | Mounjaro | Ozempic |
|---|---|---|
| Made by | Eli Lilly and Company | Novo Nordisk |
| Medicine | Tirzepatide[1] | Semaglutide[2] |
| How it acts | Activates the GIP and GLP-1 receptors[1] | Activates the GLP-1 receptor[2] |
| Approved in the US for | Type 2 diabetes (adults and children 10 and older); lowering heart risk in adults with type 2 diabetes at high risk[1] | Type 2 diabetes (adults); lowering heart risk in type 2 diabetes with heart disease; lowering kidney risk in type 2 diabetes with chronic kidney disease[2] |
| Weight management | Not in the US, where tirzepatide for weight is Zepbound; licensed for it in the UK[1][7][9] | Not in the US, where semaglutide for weight is Wegovy[2][8] |
| How it's taken | Weekly injection, any time of day, with or without meals[1] | Weekly injection on the same day each week, any time of day, with or without meals[2] |
| Strengths | 2.5, 5, 7.5, 10, 12.5 and 15 mg[1] | 0.25, 0.5, 1 and 2 mg[2] |
| Forms | Single-dose pen or vial, multi-dose vial, four-dose KwikPen[1] | Multi-dose pens, single-dose prefilled syringes[2] |
| Half-life | About 5 days[1] | About 1 week[2] |
| Most common side effects | Nausea, diarrhea, less appetite, vomiting, constipation, indigestion[1] | Nausea, vomiting, diarrhea, stomach pain, constipation[2] |
| Boxed warning | Thyroid C-cell tumors seen in rodents[1] | Thyroid C-cell tumors seen in rodents[2] |
| First US approval | 2022[1] | 2017[2] |

*From the US labels effective August 27, 2026 (Mounjaro) and June 1, 2026 (Ozempic). None of this is a dose to take; your prescriber sets that.*

## Is Mounjaro the same as Ozempic?

No. They share GLP-1 action, a weekly schedule and much of their side-effect profile, but they are different molecules from different companies.

**What they share**
- A weekly injection into the abdomen, thigh or upper arm (for Mounjaro, an upper-arm injection is given by someone else).[1][2]
- GLP-1 action, which lowers blood sugar and slows how quickly the stomach empties.[1][2]
- The same boxed warning, and the same main reason not to use them: a personal or family history of medullary thyroid cancer or MEN 2.[1][2]
- An approval to lower the risk of heart attack, stroke and cardiovascular death in some adults with type 2 diabetes.[1][2]

**Where they differ**
- **Receptors:** Mounjaro acts on GIP as well as GLP-1.[1]
- **Half-life:** about 5 days for Mounjaro, about 1 week for Ozempic.[1][2]
- **Other approvals:** Mounjaro for children 10 and older; Ozempic for chronic kidney disease in type 2 diabetes.[1][2]
- **UK licence:** Mounjaro also covers weight management there.[9]

## How each one works

Both act on receptors for hormones made in the gut. Semaglutide activates the GLP-1 receptor; tirzepatide is a single molecule that activates two, GIP and GLP-1.[1][2] Both lower blood sugar and slow how quickly the stomach empties, an effect Mounjaro's label says is largest after the first dose and fades over time.[1][2]

Does the second receptor make tirzepatide better? Zepbound's label, for the same molecule, is careful: GLP-1 is a natural regulator of appetite and calorie intake, and nonclinical studies suggest GIP "may further contribute" to regulating food intake.[7] A design difference isn't proof; the head-to-head trials below compare the results.

Tirzepatide's half-life is about 5 days, and its level steadies after about 4 weeks of weekly doses. Semaglutide's is about 1 week; its level steadies after 4 to 5 weeks, and it stays in the body for about 5 weeks after the last dose.[1][2]

## Mounjaro vs Ozempic for type 2 diabetes: SURPASS-2

SURPASS-2 compared the two directly, in an open-label trial funded by Lilly, which makes Mounjaro. It randomly assigned 1,879 adults with type 2 diabetes who were taking metformin to Mounjaro 5, 10 or 15 mg or to semaglutide 1 mg, one of Ozempic's strengths, once a week for 40 weeks.[2][3]

| After 40 weeks | Semaglutide 1 mg | Mounjaro 5 mg | Mounjaro 10 mg | Mounjaro 15 mg |
|---|---|---|---|---|
| Change in HbA1c | −1.9 points | −2.0 points | −2.2 points | −2.3 points |
| Reached HbA1c below 7% | 79% | 82% | 86% | 86% |
| Change in weight | −5.7 kg | −7.6 kg | −9.3 kg | −11.2 kg |

*Averages from the Mounjaro prescribing information, Table 5 (modified intention-to-treat population, including data after rescue medication).[1] The journal abstract gives the HbA1c changes to two decimals: −2.01, −2.24 and −2.30 points against −1.86.[3]*

Each row compares like with like: one trial, one group of people, the same 40 weeks. On average, every Mounjaro dose lowered HbA1c and weight more than semaglutide 1 mg, and the gap grew with the dose.[1] Two limits: Ozempic's 2 mg strength wasn't tested,[2] and an average is the middle of a wide spread of results, not a prediction for you.

The heart approvals rest on different trials. Ozempic's came from SUSTAIN 6, against placebo. Mounjaro's came from SURPASS-CVOT, against another GLP-1 medicine, dulaglutide, where Mounjaro was non-inferior and superiority was not established.[1][2]

## Mounjaro vs Ozempic for weight loss

In the US, neither is approved for weight management; the same molecules are sold for weight as Zepbound and Wegovy.[7][8] In the UK, Mounjaro itself is licensed for it.[9] With type 2 diabetes, SURPASS-2 is the fair comparison: 7.6 to 11.2 kg lost on average over 40 weeks on Mounjaro (5 to 15 mg) against 5.7 kg on semaglutide 1 mg.[1]

Without type 2 diabetes, the fair comparison is SURMOUNT-5, published in the New England Journal of Medicine in 2025. It randomly assigned 751 adults with obesity, or overweight with a weight-related condition, to the highest dose each person tolerated of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg, the strengths sold as Wegovy) for 72 weeks, with diet and activity counseling. It was open-label, so people knew which medicine they were taking, and it was funded by Lilly.[4][5][8]

- **−20.2%** — Average weight change on tirzepatide at 72 weeks[4]
- **−13.7%** — Average weight change on semaglutide at 72 weeks[4]
- **22.8 vs 15.0 kg** — Average weight lost, tirzepatide vs semaglutide[5]
- **−18.4 vs −13.0 cm** — Average change in waist size[4]

*SURMOUNT-5, treatment-regimen estimand: everyone randomized is counted, whether or not they kept taking their medicine. The difference in weight change was statistically significant (P<0.001).[4][5] More detail in [semaglutide vs tirzepatide](https://handlehealth.co/semaglutide-vs-tirzepatide).*

> **Reading trial numbers fairly**
> - **Compare within one trial.** Separate trials enrolled different people, at different doses, for different lengths of time.
> - **Check who was studied.** At 15 mg, tirzepatide's 72-week placebo-controlled trials found an average weight change of −20.9% in people without diabetes and −14.7% in people with type 2 diabetes, so the two kinds of result aren't interchangeable.[7]
> - **Check the analysis.** Figures that assume everyone stayed on treatment come out larger than the ones used here.
> - **Averages aren't promises.** Weight that moves the wrong way is a signal worth discussing, not a failure.

## Mounjaro vs Ozempic side effects

The most common side effects of both are digestive, and most reports of nausea, vomiting and diarrhea came while the dose was being stepped up.[1][2] In SURPASS-2, the published rates were similar: nausea in 17% to 22% of people on Mounjaro and 18% on semaglutide 1 mg, diarrhea in 13% to 16% and 12%, and vomiting in 6% to 10% and 8%.[3]

Each label also has its own placebo-controlled table. They come from different trials, and the labels say rates can't be directly compared between medicines.[1][2]

### Mounjaro label: type 2 diabetes trials

| Side effect | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 4% | 12% | 15% | 18% |
| Diarrhea | 9% | 12% | 13% | 17% |
| Decreased appetite | 1% | 5% | 10% | 11% |
| Vomiting | 2% | 5% | 5% | 9% |
| Constipation | 1% | 6% | 6% | 7% |
| Indigestion | 3% | 8% | 8% | 5% |
| Stomach pain | 4% | 6% | 5% | 5% |

*SURPASS-1 and SURPASS-5 pooled (Mounjaro prescribing information, Table 1). Stopped because of digestive side effects: 3.0%, 5.4% and 6.6% on 5, 10 and 15 mg, against 0.4% on placebo.[1]*

### Ozempic label: type 2 diabetes trials

| Side effect | Placebo | 0.5 mg | 1 mg |
|---|---|---|---|
| Nausea | 6.1% | 15.8% | 20.3% |
| Vomiting | 2.3% | 5.0% | 9.2% |
| Diarrhea | 1.9% | 8.5% | 8.8% |
| Stomach pain | 4.6% | 7.3% | 5.7% |
| Constipation | 1.5% | 5.0% | 3.1% |

*Two placebo-controlled trials pooled (Ozempic prescribing information, Table 1). Stopped because of digestive side effects: 3.1% on 0.5 mg and 3.8% on 1 mg, against 0.4% on placebo.[2]*

### Side effects in the SURMOUNT-5 trial

In SURMOUNT-5, the most common adverse events in both groups were digestive, and most were mild to moderate and occurred mainly during dose escalation.[4] Registry results show nausea in 43.6% on tirzepatide and 44.4% on semaglutide, vomiting in 15.0% and 21.3%, and injection-site reactions in 8.6% and 0.3%.[6] 6.1% and 8.0% stopped because of an adverse event; the trial wasn't designed to compare safety.[5]

### Worth knowing about both

- **Low blood sugar** is uncommon with either on its own and more likely alongside insulin or a sulfonylurea; your prescriber may adjust those medicines.[1][2]
- **Shared warnings:** pancreatitis, gallbladder problems, kidney problems from dehydration, severe stomach side effects and diabetic retinopathy complications.[1][2]
- **Before surgery or sedation,** both labels ask you to tell your care team that you take it.[1][2]
- **The contraceptive pill:** Mounjaro's label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and after each dose increase.[1]

More in [Mounjaro side effects](https://handlehealth.co/mounjaro-side-effects) and [Ozempic side effects](https://handlehealth.co/ozempic-side-effects).

> **Get medical help straight away if you have**
> - Severe stomach pain that won't go away, sometimes spreading to your back, with or without vomiting. Both labels warn about pancreatitis.[1][2]
> - Signs of a serious allergic reaction, such as swelling of the face, lips, tongue or throat, or trouble breathing.[1][2]
> - Nausea, vomiting or diarrhea that won't go away. Both labels warn that losing fluids (dehydration) can lead to kidney problems.[1][2]

### Note how you feel in seconds, on either medicine (in Handle)

Handle's daily check-in asks about nausea every day, plus the few symptoms you choose, such as diarrhea, constipation or heartburn. It stays the same short card, whatever you answer.

Some answers, such as severe nausea, come with a clear next step, like contacting your care team. Handle never diagnoses, and it is not a monitoring or emergency service: if you feel very unwell, contact your clinician or emergency services directly.

- Nausea every day; other symptoms if you switch them on
- Up to six extra tracked symptoms, or one in your own words
- Missed a day? Add it later, up to 30 days back

## Ozempic vs Wegovy vs Mounjaro: how the brands fit together

Much of the confusion comes from each molecule having more than one brand: Ozempic and Wegovy are both semaglutide from Novo Nordisk, and Mounjaro and Zepbound are both tirzepatide from Eli Lilly.[1][2][7][8] See [Ozempic vs Wegovy](https://handlehealth.co/ozempic-vs-wegovy), [Mounjaro vs Zepbound](https://handlehealth.co/mounjaro-vs-zepbound), or every brand in our [guide to GLP-1 medications](https://handlehealth.co/glp-1-medications).

| Brand | Medicine | Approved in the US for | Taken as |
|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes; lowering heart and kidney risks[2] | Weekly injection |
| Wegovy | Semaglutide | Weight management; lowering heart risk; a liver disease called MASH[8] | Weekly injection or daily pill |
| Mounjaro | Tirzepatide | Type 2 diabetes; lowering heart risk (weight management too in the UK)[1][9] | Weekly injection |
| Zepbound | Tirzepatide | Weight management; obstructive sleep apnea[7] | Weekly injection |

*In the US, "Ozempic" can now also mean Ozempic tablets, a daily semaglutide pill for type 2 diabetes (the newer Rybelsus strengths, renamed in 2026).[11] Here, Ozempic means the weekly injection. Saxenda (liraglutide 3 mg), another Novo Nordisk weight-management injection, is being discontinued in the US, with last shipments due in late January 2027.[12]*

## Strengths, pens and storage: facts, not instructions

Mounjaro comes in six strengths, 2.5 to 15 mg, as single-dose pens or vials, or as four-dose multi-dose vials and KwikPens.[1] Ozempic comes in four, 0.25 to 2 mg, in multi-dose pens or single-dose syringes.[2]

Both labels start low and step up gradually (to reduce stomach side effects, Ozempic's label says), and your prescriber sets the steps.[2] There is no equivalent dose between the two molecules: a number on one pen tells you nothing about the other.

Each medicine has its own missed-dose rule, and they differ, so ask your prescriber or pharmacist. Handle records what happened and never tells you to catch up. For storage, Mounjaro lives in the fridge (a single-dose pen or vial can spend up to 21 days in total at up to 30 °C); an opened Ozempic pen keeps for 56 days at room temperature or in the fridge.[1][2]

## Cost and coverage

Prices, insurance coverage and NHS or private access change often and vary by country and plan, so we don't quote them here; your insurer, pharmacy or prescriber can tell you what applies. Coverage can depend on why a medicine is prescribed: in the US, Mounjaro and Ozempic are diabetes medicines, while Zepbound and Wegovy are the weight-management brands.[1][2][7][8]

## Switching between Mounjaro and Ozempic

Whether to switch, when, and at what dose is your prescriber's decision, and there is no conversion chart between the two molecules. The labels for Zepbound and Wegovy, the weight-management brands of the same molecules, both say they are not recommended alongside another GLP-1 medicine.[7][8]

### What to record if your prescriber switches you

- **Your last dose of the old medicine.** Date, amount and injection site.
- **Your first dose of the new one.** Date, amount, site, and the pen or vial type.
- **How you feel in the first weeks.** Nausea, appetite and bowel changes, briefly.
- **Your weight trend across the change.** Weekly averages, not single mornings.
- **Anything else that changed.** A gap between medicines, or a new medicine alongside.

In Handle, both medicines stay on one record: update your plan when your prescriber changes it, and every earlier dose stays in the same history. Journey draws your dose as a step line beneath your weight, so the week the medicine changed is easy to find, and it never says one caused the other.

## Mounjaro and Ozempic in the UK

In the UK, where there is no Zepbound brand, Mounjaro is licensed for weight management as well as type 2 diabetes; the MHRA authorised the weight-management use in November 2023.[9] NICE recommends tirzepatide for managing obesity in adults with a BMI of at least 35 and at least one weight-related condition, with lower thresholds for some ethnic backgrounds, and NHS access is being phased in.[10]

For semaglutide's weight-management brand, see [Mounjaro vs Wegovy](https://handlehealth.co/mounjaro-vs-wegovy). Jab or injection, NHS or private, Handle records it the same way; the [Mounjaro tracker](https://handlehealth.co/mounjaro-tracker) and [Ozempic tracker](https://handlehealth.co/ozempic-tracker) pages show how.

## Questions to bring to your prescriber

Whichever medicine you're offered, these make the appointment more useful.

1. Given my health, which of these fits me better, and why?
2. What result would tell us this is working, and when will we review it?
3. Which side effects should I call you about, and which can I manage at home?
4. Does either one affect my other medicines, such as insulin, a sulfonylurea or the contraceptive pill?
5. What does my insurance or NHS route cover, and would a switch change that?
6. If we switch later, how will we do it, and what should I keep a record of?

### Bring your own record, not just the trial averages (Handle Premium)

Trials tell you what happened on average. A consultation report shows what happened to you: your medication record including any switch, your weight history, symptom summaries, nutrition and activity, and a note about what you want to discuss. Read more about [preparing for a GLP-1 doctor appointment](https://handlehealth.co/glp-1-doctor-appointment).

- Share a secure link, and revoke it whenever you like
- Your private daily notes are never included
- Your clinician needs no account to read it

## Questions people ask

### Is Mounjaro better than Ozempic?

It depends on what matters to you. In SURPASS-2, adults with type 2 diabetes lowered HbA1c and weight more on Mounjaro than on semaglutide 1 mg, on average; in SURMOUNT-5, in adults without type 2 diabetes, tirzepatide led to more weight loss than semaglutide at Wegovy's strengths.[1][4] Digestive side effects were broadly similar. Your health, other medicines and coverage matter too, so decide with your prescriber.

### Is Mounjaro the same as Ozempic?

No. Mounjaro is tirzepatide, made by Eli Lilly, and activates both GIP and GLP-1 receptors. Ozempic is semaglutide, made by Novo Nordisk, and activates GLP-1 receptors only.[1][2] They're compared so often because both are once-weekly injections approved in the US for type 2 diabetes, with similar digestive side effects.

### Which is better for weight loss, Mounjaro or Ozempic?

Neither is approved for weight management in the US, where the same molecules are sold for weight as Zepbound and Wegovy.[7][8] In SURMOUNT-5 (adults without type 2 diabetes), average weight change over 72 weeks was −20.2% on tirzepatide (10 or 15 mg) and −13.7% on semaglutide (1.7 or 2.4 mg), counting everyone randomized.[4] In SURPASS-2 (type 2 diabetes), people lost 7.6 to 11.2 kg over 40 weeks on Mounjaro (5 to 15 mg) and 5.7 kg on semaglutide 1 mg.[1] These are averages, not promises.

### Does Mounjaro have more side effects than Ozempic?

Not clearly. In SURPASS-2 (type 2 diabetes, 40 weeks), nausea affected 17% to 22% on Mounjaro and 18% on semaglutide 1 mg, with similar rates of diarrhea and vomiting.[3] In SURMOUNT-5 (adults without type 2 diabetes, 72 weeks), 6.1% on tirzepatide and 8.0% on semaglutide stopped because of an adverse event, though the trial wasn't designed to compare safety.[5] With both, stomach side effects are most common while the dose is being stepped up.[1][2]

### Is Mounjaro stronger than Ozempic?

The milligram numbers can't be compared. Mounjaro comes in 2.5 to 15 mg and Ozempic in 0.25 to 2 mg because they are different molecules, so a bigger number doesn't mean a stronger medicine.[1][2] What can be compared is results within one trial: in SURPASS-2, in adults with type 2 diabetes, each Mounjaro dose lowered HbA1c and weight more than semaglutide 1 mg over 40 weeks, on average.[1]

### Can I switch from Ozempic to Mounjaro?

Your prescriber can switch you, and they decide when and at what dose; there's no conversion chart between the two. If you switch, record the date and amount of your last and first doses, how you feel in the first weeks and your weight trend. Handle keeps both medicines in one history, so the change is easy to show at appointments.

### How long does Mounjaro stay in your system compared with Ozempic?

Tirzepatide's half-life is about 5 days, and its level steadies after about 4 weeks of weekly doses.[1] Semaglutide's half-life is about 1 week; its level steadies after 4 to 5 weeks, and it stays in the body for about 5 weeks after the last dose.[2] Handle's Between doses, part of Premium in the iPhone app, estimates your level from the doses you recorded. It's a model, not a blood test. More in our guides to the [Mounjaro half-life](https://handlehealth.co/mounjaro-half-life) and the [Ozempic half-life](https://handlehealth.co/ozempic-half-life).

### Can Handle track Mounjaro and Ozempic?

Yes. Both are in Handle's medicine list: record your prescribed plan, log each dose with its time and injection site, and add a short daily check-in, weight, food and fluids. If your prescriber switches you, both medicines stay on one record. All of that is free; Premium, an optional subscription in the iPhone app, adds the Between doses estimate and a shareable consultation report.

## Sources

1. Eli Lilly and Company, via DailyMed (U.S. National Library of Medicine). [Mounjaro (tirzepatide) injection — Prescribing Information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0), effective August 27, 2026.
2. Novo Nordisk, via DailyMed (U.S. National Library of Medicine). [Ozempic (semaglutide) injection — Prescribing Information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79), effective June 1, 2026.
3. Frías JP et al., New England Journal of Medicine 2021;385:503–515, via PubMed. [Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)](https://pubmed.ncbi.nlm.nih.gov/34170647/), 2021.
4. Aronne LJ et al., New England Journal of Medicine 2025;393:26–36, via PubMed. [Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)](https://pubmed.ncbi.nlm.nih.gov/40353578/), May 11, 2025.
5. Eli Lilly and Company (press release). [Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine](https://www.prnewswire.com/news-releases/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy-semaglutide-in-complete-surmount-5-results-published-in-the-new-england-journal-of-medicine-302451241.html), May 11, 2025.
6. ClinicalTrials.gov (U.S. National Library of Medicine). [A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5, NCT05822830): results](https://clinicaltrials.gov/study/NCT05822830).
7. Eli Lilly and Company, via DailyMed (U.S. National Library of Medicine). [Zepbound (tirzepatide) injection — Prescribing Information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b), effective August 28, 2026.
8. Novo Nordisk, via DailyMed (U.S. National Library of Medicine). [Wegovy (semaglutide) injection and tablets — Prescribing Information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b), effective June 18, 2026.
9. Medicines and Healthcare products Regulatory Agency (UK). [MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss](https://www.gov.uk/government/news/mhra-authorises-diabetes-drug-mounjaro-tirzepatide-for-weight-management-and-weight-loss), November 8, 2023.
10. National Institute for Health and Care Excellence. [Tirzepatide for managing overweight and obesity (TA1026)](https://www.nice.org.uk/guidance/ta1026), updated September 1, 2025.
11. Novo Nordisk, via DailyMed (U.S. National Library of Medicine). [Rybelsus and Ozempic (semaglutide) tablets — Prescribing Information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98), effective January 30, 2026.
12. Novo Nordisk (NovoMedLink). [Saxenda (liraglutide) Injection 3 mg Official Physician Site: discontinuation notice](https://www.novomedlink.com/obesity/products/treatments/saxenda.html), accessed September 23, 2026.

## About Handle

Handle is a GLP-1 treatment companion. It keeps your dose record, a short daily check-in, weight, food, drinks and activity in one calm place, and turns them into a summary you can choose to share with your clinician.

Handle supports recording and conversations with your care team. It does not diagnose, and it never tells you to start, change, skip or stop a dose. This page is general information, not medical advice. Always follow your prescriber and your medicine's instructions for use.